Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Biobreath DM is a branded generic oral syrup developed and marketed by Kaiser Pharmaceutical, an Indian pharmaceutical company. It is a combination medication formulated for the symptomatic relief of dry cough and allergic symptoms associated with the common cold, flu, or upper respiratory tract infections. The formulation typically contains dextromethorphan hydrobromide, a non-opioid antitussive that acts centrally on the cough center in the medulla to suppress the cough reflex, and chlorpheniramine maleate, a first-generation antihistamine that blocks H1 receptors to alleviate symptoms such as sneezing, runny nose, and watery eyes. As a marketed product, it is used in clinical practice for patients requiring both cough suppression and antihistaminic action.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Biobreath DM.